

**PRESS RELEASE****NANOBIOTIX TO PARTICIPATE IN JEFFERIES LONDON HEALTHCARE CONFERENCE**

**Paris, France; Cambridge, Massachusetts (USA); November 11, 2025** - [NANOBIOTIX](#) (Euronext: NANO - NASDAQ: NBTX - the “**Company**”), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in a fireside chat at the following conference:

**Jefferies London Healthcare Conference**

Date: Monday, November 17, 2025

Time: 3pm GMT / 10am ET / 4pm CET

Location: London, UK

Presenters: Laurent Levy, Chief Executive Officer of Nanobiotix and Bart van Rhijn, Chief Financial & Business Officer of Nanobiotix

Webcast link: [Click here](#)

The fireside chat will be webcast live from the [events page](#) of the Investors section of the Company’s website. Replay of the webcast will be available following the event.

\*\*\*

**About NANOBIOTIX**

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

For more information about Nanobiotix, visit us at [www.nanobiotix.com](http://www.nanobiotix.com) or follow us on [LinkedIn](#) and [Twitter](#).

**Contacts**

| <i>Nanobiotix</i>  |  |
|--|--|
| <b>Communications Department</b><br><i>Brandon Owens</i><br><i>VP, Communications</i><br>+1 (617) 852-4835<br><a href="mailto:contact@nanobiotix.com">contact@nanobiotix.com</a> | <b>Investor Relations Department</b>   |
|  | <i>Joanne Choi</i><br><i>VP, Investor Relations (US)</i><br>+1 (713) 609-3150          |
|  | <i>Ricky Bhajun</i><br><i>Director, Investor Relations (EU)</i><br>+33 (0) 79 97 29 99 |
|  | <a href="mailto:investors@nanobiotix.com">investors@nanobiotix.com</a>                 |
|  | <i>Media Relations</i>   |

France – **HARDY**

Caroline Hardy

+33 06 70 33 49 50

[carolinehardy@outlook.fr](mailto:carolinehardy@outlook.fr)

---

Global – **uncapped**

Becky Lauer

+1 (646) 286-0057

[uncappednanobiotix@uncappedcommunications.com](mailto:uncappednanobiotix@uncappedcommunications.com)

**NBTX** **NANO**  
Nasdaq Listed **LISTED**  
EURONEXT